AMERICAN ASSOCIATION FOR CANCER RESEARCH for AMERICAN ASSOCIATION FOR CANCER RESEARCH
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 18, 2022 | $100,000 | Replaced |
| 2nd Quarter - Amendment | Oct 19, 2022 | $100,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Cancer health disparities HPV-related cancers - prevention, screening, diagnosis and treatment HPV vaccination Cancer survivorship
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANA MILLER ACTON New | — |
| MARC JOHNSON | — |
Budget/Appropriations BUD
FY 2023 Appropriations for the National Institutes of Health FY 2023 Appropriations for the Centers for Disease Control and Prevention FY 2023 Appropriations for the Food and Drug Administration FY 2023 Appropriations for the Congressionally Directed Medical Research Programs at the Department of Defense
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANA MILLER ACTON | — |
| MARC JOHNSON | — |
Medical/Disease Research/Clinical Labs MED
Cancer research Oncology product review at the FDA Pediatric research and cancer care Clinical trials Diversity in clinical trials
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANA MILLER ACTON New | — |
| MARC JOHNSON | — |
Tobacco TOB
Tobacco control measures E-cigarette regulation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANA MILLER ACTON New | — |
| MARC JOHNSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.